Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

about

Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Item

http://www.wikidata.org/entity/Q47871565

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Current Therapies That Modify ...... Effect of Such Modifications?

@en

Current Therapies That Modify ...... Effect of Such Modifications?

@nl

type

Item

label

Current Therapies That Modify ...... Effect of Such Modifications?

@en

Current Therapies That Modify ...... Effect of Such Modifications?

@nl

prefLabel

Current Therapies That Modify ...... Effect of Such Modifications?

@en

Current Therapies That Modify ...... Effect of Such Modifications?

@nl

P1476

Current Therapies That Modify ...... Effect of Such Modifications?

@en

P2093

Magnus F Grøndahl

http://www.w3.org/2001/XMLSchema#string

Tina Vilsbøll

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Glucagon and heart in type 2 diabetes: new perspectives

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

The Physiology of Glucagon-like Peptide 1

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans.

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

P2888

s11892-017-0967-z

P304

128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11892-017-0967-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Filip K Knop

Damien J Keating

P577

2017-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29080075

http://www.w3.org/2001/XMLSchema#string